

Human Papillomavirus (HPV) Vaccine Session

Joseph A. Bocchini, Jr., MD
Chair, ACIP HPV Vaccine Work Group

Advisory Committee on Immunization Practices
Atlanta, GA
June 25, 2014

Today's HPV session

- ❑ **Investigational 9-valent HPV vaccine**
 - Clinical trial data
 - Policy questions and approach to GRADE
- ❑ **2-dose HPV vaccination schedules**

ACIP HPV vaccine workgroup activities

- ❑ **Preparing for licensure of 9-valent HPV vaccine**
 - Potential licensure late 2014

- ❑ **Continuing to review data on 2-dose schedules**
 - GSK presentation on 2-dose development program (2013)
 - WG presentation and review of data (2014)

Overview of ACIP timeline for consideration of 9-valent HPV vaccine

ACIP Date	Topic
Oct 2013	Overview of 9-valent vaccine clinical program
Feb 2014	Attribution of types in HPV-associated disease Clinical trial data
June 2014	Clinical trial data GRADE Policy Questions
Oct 2014	Health Economics GRADE Recommendation options and discussion
Feb 2015	Earliest potential vote

Outline of HPV ACIP session

- ❑ 9-valent HPV vaccine clinical trial data
 - Dr. Alain Luxembourg, Merck

- ❑ Policy considerations and approach to GRADE for 9-valent vaccine
 - Dr. Eileen Dunne, NCHHSTP, CDC

- ❑ 2-dose schedules – bivalent and quadrivalent HPV vaccines
 - Dr. Lauri Markowitz, NCHHSTP, CDC

ACIP HPV Vaccine Workgroup members

ACIP Members

Joseph Bocchini (WG chair)
Tamera Coyne-Beasley
Renee Jenkins
Allison Kempe
Jose Romero
Laura Riley

Ex Officio Members

Carolyn Deal (NIH)
Bruce Gellin (NVPO)
Nancy Miller (FDA)
Jeff Roberts (FDA)

CDC Lead

Lauri Markowitz

Liasion Representatives

Sandra Fryhofer (ACP)
Amy Middleman (SAM)
James Turner (ACHA)
Patricia Whitley-Williams (NMA)
Rodney Willoughby (AAP)
Jane Zucker (AIM)
Margo Savoy (AAFP)
Linda Eckert (AGOG)

Consultants

John Douglas
Janet Englund
Sam Katz
Debbie Saslow (ACS)
Aimee Kreimer (NCI)